



#120  
Dec  
4/14/03

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: **Keith D. ALLEN *et al.***

Serial No.: **10/010,065**

Filed: **December 5, 2001**

Title: **Transgenic Mice Containing Glucagon  
Receptor Gene Disruptions**

Group Art Unit: **1632**

Examiner: **Bertoglio, Valerie E**

Customer No. **26619**

Docket/Order No. **R-648**

Date: **April 7, 2003**

**AMENDMENT**

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In response to the Office Action mailed January 7, 2003 in connection with the above-identified application, Applicants request entry and consideration of the following amendments and remarks.

**RECEIVED**

**APR 15 2003**

**TECH CENTER 1600/2900**

**THE AMENDMENTS**

**In the Claims:**

Please cancel claims 5-10 and 18-34.

Please add claims 57-71 below.

57. (New) A transgenic mouse whose genome comprises a disruption in an endogenous glucagon receptor gene, wherein where the disruption is homozygous, the transgenic mouse exhibits, relative to a wild-type mouse, a metabolic abnormality or a pancreatic abnormality.
58. (New) The transgenic mouse of claim 57, wherein the metabolic abnormality comprises a decreased fasting blood glucose level.
59. (New) The transgenic mouse of claim 58, wherein the metabolic abnormality comprises increased glucose tolerance.
60. (New) The transgenic mouse of claim 59, wherein the increased glucose tolerance is characterized by a decreased blood glucose level following glucose administration.